Gastric pre-processing is an important determinant of the ability of medium-chain lipid solution formulations to enhance oral bioavailability in rats

Journal of Pharmaceutical Sciences

Volumn 102, Issue 11, 2013, Pages 3957-3965

  Lee, Kathy Wai Yu ^a   Porter, Christopher J H ^a   Boyd, Ben J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Absorption; Bioavailability; Emulsion; Lipids; Poorly water soluble drug

Indexed keywords

CINNARIZINE; LIPID; LONG CHAIN TRIACYLGLYCEROL; MEDIUM CHAIN TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; MALE; MICELLE; NONHUMAN; RAT; SMALL INTESTINE; STOMACH;

ABSORPTION; BIOAVAILABILITY; EMULSION; LIPIDS; POORLY WATER-SOLUBLE DRUG;

ADMINISTRATION, ORAL; ANIMALS; CALCIUM CHANNEL BLOCKERS; CINNARIZINE; EMULSIONS; MALE; PHARMACEUTICAL VEHICLES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STOMACH; TRIGLYCERIDES;

EID: 84885840519     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23690     Document Type: Article

References (39)

1. Porter CJH, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs, Nat Rev Drug Discov 6:231-248.
2. Pouton CW. 2000. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems, Eur J Pharm Sci 11:S93-S98.
3. Humberstone AJ, Charman WN. 1997. Lipid-based vehicles for the oral delivery of poorly water soluble drugs, Adv Drug Deliv Rev 25:103-128.
4. Cohen M, Morgan RG, Hofmann AF. 1971. Lipolytic activity of human gastric and duodenal juice against medium and long chain triglycerides, Gastroenterology 60:1-15.
5. Schonheyder F, Volqvartz K. 1946. The gastric lipase in man, Acta Physiol Scand 11:349-360.
6. DeNigris SJ, Hamosh M, Kasbekar DK, Fink CS, Lee TC, Hamosh P. 1985. Secretion of human gastric lipase from dispersed gastric glands, Biochim Biophys Acta 836:67-72.
7. Armand M, Hamosh M, DiPalma JS, Gallagher J, Benjamin SB, Philpott JR, Lairon D, Hamosh P. 1995. Dietary-fat modulates gastric lipase activity in healthy humans, Am J Clin Nutr 62:74-80.
8. Kossena GA, Charman WN, Wilson CG, O'Mahony B, Lindsay B, Hempenstall JM, Davison CL, Crowley PJ, Porter CJH. 2007. Low dose lipid formulations: Effects on gastric emptying and biliary secretion, Pharm Res 24:2084-2096.
9. Matzinger D, Degen L, Drewe J, Meuli J, Duebendorfer R, Ruckstuhl N, D'Amato M, Rovati L, Beglinger C. 2000. The role of long chain fatty acids in regulating food intake and cholecytokinin release in humans, Gut 46:688-693.
10. ® 44/14, Pharm Res 26:1901-1910.
11. app = 8, J Chromatogr 629:123-134.
12. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12:412-420.
13. Edwards GA, Porter CJH, Caliph SM, Khoo S-M, Charman WN. 2001. Animal models for the study of intestinal lymphatic drug transport, Adv Drug Deliv Rev 50:45-60.
14. Lee KWY, Porter CJH, Boyd BJ. 2012. The effect of administered dose of lipid-based formulations on the in vitro and in vivo performance of cinnarizine as a model poorly water-soluble drug, J Pharm Sci 102:565-578.
15. Kossena GA, Boyd BJ, Porter CJH, Charman WN. 2003. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs, J Pharm Sci 92:634-648.
16. Sek L, Porter CJH, Charman WN. 2001. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis, J Pharm Biomed Anal 25:651-661.
17. Kaukonen AM, Boyd BJ, Porter CJH, Charman WN. 2004. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations, Pharm Res 21:245-253.
18. Kossena GA, Charman WN, Boyd BJ, Porter CJH. 2004. A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs, J Control Release 99:217-229.
19. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S. 1992. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies, Int J Pharm 82:1-7.
20. Porter CJH, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, O'Connor JM, Edwards GA, Charman WN. 2004. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine, J Pharm Sci 93:1110-1121.
21. Nguyen T-H, Hanley T, Porter CJH, Larson I, Boyd BJ. 2010. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation, J Pharm Pharmacol 62:856-865.
22. Armand M, Borel P, Dubois C, Senft M, Peyrot J, Salducci J, Lafont H, Lairon D. 1994. Characterization of emulsions and lipolysis of dietary lipids in the human stomach, Am J Physiol 266:G372-G381.
23. Armand M, Borel P, Pasquier B, Dubois C, Senft M, Andre M, Peyrot J, Salducci J, Lairon D. 1996. Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum, Am J Physiol 34:G172-G183.
24. Bach AC, Babayan VK. 1982. Medium-chain triglycerides: An update, Am J Clin Nutr 36:950-962.
25. Marten B, Pfeuffer M, Schrezenmeir J. 2006. Medium-chain triglycerides, Int Dairy J 16:1374-1382.
26. McClements DJ, Li Y. 2010. Sturctured emulsion-based delivery systens: Controlling the digestion and release of lipophilic food components, Adv Colloid Interface Sci 159:213-228.
27. Liao TH, Hamosh P, Hamosh M. 1984. Fat digestion by lingual lipase: Mechanism of lipolysis in the stomach and upper small intestine, Pediatr Res 18:402-409.
28. Hamosh M, Bitman J, Liao TH, Mehta NC, Buczek RJ, Wood DL, Grylack LJ, Hamosh P. 1989. Gastric lipolysis and fat absorption in preterm infants: Effect of medium-chain triglyceride or long-chain triglyceride-containing formulas, Pediatrics 83:86-92.
29. ®, medium chain glycerides and PEG esters, Biochim Biophys Acta 1771:633-640.
30. Palin KJ, Phililips AJ, Ning A. 1986. The oral absorption of cefoxitin from oil and emulsion vehicles in rats, Int J Pharm 33:99-104.
31. Myers RA, Stella VJ. 1992. Systemic bioavailability of penclomedine (NSC-338720) from oil-in-water emulsions administered intraduodenally to rats, Int J Pharm 78:217-226.
32. Alvarez FJ, Stella VJ. 1989. Pancreatic lipase-catalyzed hydrolysis of esters of hydroxymethyl phenytoin dissolved in various metabolizable vehicles, dispersed in micellar systems, and in aqueous suspensions, Pharm Res 6:555-563.
33. Anby MU, Williams HD, McIntosh M, Benameur H, Edwards GA, Pouton CW, Porter CJH. 2012. Lipid digestion as a trigger for supersaturation: Evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems, Mol Pharm 9:2063-2079.
34. Williams HD, Anby MU, Sassene P, Kleberg K, Bakala-N'Goma J, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carrière F, Müllertz A, Pouton CW, Porter CJH. 2012. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion, Mol Pharm 9:3286-3300.
35. Sassene PJ, Knopp MM, Hesselkilde JZ, Koradia V, Larsen A, Rades T, Müllertz A. 2010. Precipitation of a poorly soluble model drug during in vitro lipolysis: Characterization and dissolution of the precipitate, J Pharm Sci 99:4982-4991.
36. Carrigan PJ, Bates TR. 1973. Biopharmaceutics of drugs administered in lipid-containing dosage forms I: GI absorption of griseofulvin from an oil-in-water emulsion in the rat, J Pharm Sci 62:1476-1479.
37. Dahan A, Hoffman A. 2006. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats, Pharm Res 23:2165-2174.
38. Sek L, Porter CJH, Kaukonen AM, Charman WN. 2002. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behavior of their lipolytic products, J Pharm Pharmacol 54:29-41.
39. Dahan A, Hoffman A. 2008. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs, J Control Release 129:1-10.